Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lucentis Faces Academic Challenge

This article was originally published in The Pink Sheet Daily

Executive Summary

Funding for a multi-center trial to compare Genentech’s approved macular degeneration therapy with oncologic Avastin, used off-label to treat the disease, depends on NIH’s pending FY 2007 budget.
Advertisement

Related Content

NIH Kicks Off Head-To-Head Avastin/Lucentis Study
NIH Kicks Off Head-To-Head Avastin/Lucentis Study
Lucentis’ First Patients Mostly Taken From Macugen, Visudyne & Avastin – Genentech
Lucentis’ First Patients Mostly Taken From Macugen, Visudyne & Avastin – Genentech
Pfizer/OSI To Curtail Macugen Research In Response To Genentech Competition
Genentech’s Lucentis Ships June 30 Following Approval
Genentech’s Lucentis Ships June 30 Following Approval

Topics

Advertisement
UsernamePublicRestriction

Register

PS063321

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel